• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BCL7A 低表达预示卵巢癌预后不良。

Low BCL7A expression predicts poor prognosis in ovarian cancer.

机构信息

Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130033, People's Republic of China.

Department of Breast Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130033, People's Republic of China.

出版信息

J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.

DOI:10.1186/s13048-019-0518-0
PMID:31077237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6511192/
Abstract

BACKGROUND AND OBJECTIVE

Ovarian cancer is a common gynaecological cancer with a poor prognosis that poses a serious threat to human life and health. It is essential to explore the possible prognostic biomarkers of ovarian cancer. As an important tumour suppressor gene, BCL7A actively participates in the growth of tumours. We aimed to study the prognostic role of BCL7A in ovarian cancer.

RESULTS

Through data mining of RNAseq data from the Cancer Genome Atlas database (TCGA), we explored the clinical relevance of BCL7A mRNA expression. As a result, we found that BCL7A is expressed at low levels in ovarian cancer tissues and is correlated with survival status. Survival analysis showed that, compared with those who had higher levels of BCL7A expression, patients with ovarian cancer and low levels of BCL7A generally had shorter overall/relapse-free survival times. Cox regression models showed that low BCL7A expression could be used as an independent prognostication factor for ovarian cancer patients.

CONCLUSIONS

Low BCL7A expression is an independent risk factor for poor prognosis in ovarian cancer patients.

摘要

背景与目的

卵巢癌是一种常见的妇科癌症,预后较差,严重威胁人类生命健康。探索卵巢癌可能的预后生物标志物至关重要。BCL7A 作为一个重要的肿瘤抑制基因,积极参与肿瘤的生长。我们旨在研究 BCL7A 在卵巢癌中的预后作用。

结果

通过对癌症基因组图谱数据库(TCGA)的 RNAseq 数据进行数据挖掘,我们探讨了 BCL7A mRNA 表达的临床相关性。结果发现,BCL7A 在卵巢癌组织中表达水平较低,与生存状态相关。生存分析表明,与 BCL7A 表达水平较高的患者相比,BCL7A 水平较低的卵巢癌患者的总生存期/无复发生存期通常较短。Cox 回归模型表明,低 BCL7A 表达可作为卵巢癌患者独立的预后预测因素。

结论

低 BCL7A 表达是卵巢癌患者预后不良的独立危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7d6/6511192/0aa1665f3e56/13048_2019_518_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7d6/6511192/81ba3fc13161/13048_2019_518_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7d6/6511192/e54fb6577ea9/13048_2019_518_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7d6/6511192/0aa1665f3e56/13048_2019_518_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7d6/6511192/81ba3fc13161/13048_2019_518_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7d6/6511192/e54fb6577ea9/13048_2019_518_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7d6/6511192/0aa1665f3e56/13048_2019_518_Fig3_HTML.jpg

相似文献

1
Low BCL7A expression predicts poor prognosis in ovarian cancer.BCL7A 低表达预示卵巢癌预后不良。
J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.
2
Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.类stomatin蛋白2在上皮性卵巢癌中过表达,并预示患者预后不良。
BMC Cancer. 2015 Oct 20;15:746. doi: 10.1186/s12885-015-1723-x.
3
BCL7A as a novel prognostic biomarker for glioma patients.BCL7A 作为一种新的胶质瘤患者预后生物标志物。
J Transl Med. 2021 Aug 6;19(1):335. doi: 10.1186/s12967-021-03003-0.
4
BCL7A protein expression in normal and malignant lymphoid tissues.BCL7A蛋白在正常及恶性淋巴组织中的表达
Br J Haematol. 2013 Jan;160(1):106-9. doi: 10.1111/bjh.12080. Epub 2012 Oct 9.
5
Low EIF2B5 expression predicts poor prognosis in ovarian cancer.低EIF2B5表达预示卵巢癌预后不良。
Medicine (Baltimore). 2020 Jan;99(5):e18666. doi: 10.1097/MD.0000000000018666.
6
Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage cutaneous T-cell lymphoma.在早期皮肤T细胞淋巴瘤患者中,BCL7A表达缺失与疾病预后不良相关。
Leuk Lymphoma. 2013 Mar;54(3):653-4. doi: 10.3109/10428194.2012.717695. Epub 2012 Aug 28.
7
Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.上皮性卵巢癌中polo样蛋白激酶1、P53和P21WAF1的调控异常提示预后不良。
Oncol Rep. 2015 Mar;33(3):1235-42. doi: 10.3892/or.2015.3723. Epub 2015 Jan 15.
8
Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.阿贝尔森相互作用蛋白1的上调预示上皮性卵巢癌的肿瘤进展和不良预后。
Hum Pathol. 2015 Sep;46(9):1331-40. doi: 10.1016/j.humpath.2015.05.015. Epub 2015 May 30.
9
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.浆液性卵巢癌患者胸腹水Ets-1 mRNA表达是预后不良的一个标志物。
Am J Surg Pathol. 2001 Dec;25(12):1493-500. doi: 10.1097/00000478-200112000-00004.
10
Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study.丹麦卵巢癌研究(MALOVA):细胞周期蛋白 E 的组织蛋白表达水平对丹麦卵巢癌患者预后价值有限。
APMIS. 2012 Oct;120(10):846-54. doi: 10.1111/j.1600-0463.2012.02913.x. Epub 2012 May 10.

引用本文的文献

1
A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer.一项关于安罗替尼治疗持续性、复发性或转移性宫颈癌和子宫内膜癌患者的回顾性研究。
Transl Cancer Res. 2024 Jul 31;13(7):3718-3728. doi: 10.21037/tcr-24-272. Epub 2024 Jun 26.
2
Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer.基于免疫基因的顺铂反应模型鉴定及 CD27 作为克服卵巢癌顺铂耐药的治疗靶点
J Immunol Res. 2022 May 18;2022:4379216. doi: 10.1155/2022/4379216. eCollection 2022.
3
Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer.

本文引用的文献

1
Surgical prevention strategies in ovarian cancer.卵巢癌的手术预防策略。
Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4.
2
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials.晚期卵巢癌中密集剂量的每周化疗:随机对照试验的更新荟萃分析。
Crit Rev Oncol Hematol. 2018 May;125:30-34. doi: 10.1016/j.critrevonc.2018.02.016. Epub 2018 Mar 7.
3
Real-world evidence in the treatment of ovarian cancer.卵巢癌治疗的真实世界证据。
MAL2的过表达与乳腺癌中的免疫浸润及不良预后相关。
Evid Based Complement Alternat Med. 2021 Sep 9;2021:5557873. doi: 10.1155/2021/5557873. eCollection 2021.
4
The Immune-Related Gene ELF3 is a Novel Biomarker for the Prognosis of Ovarian Cancer.免疫相关基因ELF3是卵巢癌预后的新型生物标志物。
Int J Gen Med. 2021 Sep 10;14:5537-5548. doi: 10.2147/IJGM.S332320. eCollection 2021.
5
BCL7A as a novel prognostic biomarker for glioma patients.BCL7A 作为一种新的胶质瘤患者预后生物标志物。
J Transl Med. 2021 Aug 6;19(1):335. doi: 10.1186/s12967-021-03003-0.
6
Using bioinformatics approaches to investigate driver genes and identify BCL7A as a prognostic gene in colorectal cancer.使用生物信息学方法研究驱动基因并将BCL7A鉴定为结直肠癌的一个预后基因。
Comput Struct Biotechnol J. 2021 Jul 1;19:3922-3929. doi: 10.1016/j.csbj.2021.06.044. eCollection 2021.
7
BCL7C suppresses ovarian cancer growth by inactivating mutant p53.BCL7C 通过使突变型 p53 失活来抑制卵巢癌细胞生长。
J Mol Cell Biol. 2021 May 7;13(2):141-150. doi: 10.1093/jmcb/mjaa065.
8
SLC25A11 serves as a novel prognostic biomarker in liver cancer.SLC25A11 可作为肝癌的一种新型预后生物标志物。
Sci Rep. 2020 Jun 18;10(1):9871. doi: 10.1038/s41598-020-66837-6.
9
Ubiquitin-like modifier-activating enzyme 7 as a marker for the diagnosis and prognosis of breast cancer.泛素样修饰激活酶7作为乳腺癌诊断和预后的标志物。
Oncol Lett. 2020 Apr;19(4):2773-2784. doi: 10.3892/ol.2020.11406. Epub 2020 Feb 17.
10
Low EIF2B5 expression predicts poor prognosis in ovarian cancer.低EIF2B5表达预示卵巢癌预后不良。
Medicine (Baltimore). 2020 Jan;99(5):e18666. doi: 10.1097/MD.0000000000018666.
Ann Oncol. 2017 Nov 1;28(suppl_8):viii61-viii65. doi: 10.1093/annonc/mdx443.
4
Nintedanib in ovarian cancer.尼达尼布治疗卵巢癌。
Expert Opin Investig Drugs. 2017 Sep;26(9):1073-1081. doi: 10.1080/13543784.2017.1353599.
5
Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.晚期上皮性卵巢癌女性患者诊断前的健康相关生活质量、手术及生存情况:一项监测、流行病学和最终结果-医疗保险和医疗补助服务中心研究
Gynecol Oncol. 2017 Feb;144(2):348-353. doi: 10.1016/j.ygyno.2016.12.005. Epub 2016 Dec 14.
6
Surgery for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的手术治疗
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:71-87. doi: 10.1016/j.bpobgyn.2016.10.007. Epub 2016 Oct 20.
7
Ovarian cancer: epidemiology and risk factors.卵巢癌:流行病学与风险因素
Eur J Cancer Prev. 2017 Jan;26(1):55-62. doi: 10.1097/CEJ.0000000000000217.
8
Current state of biomarkers in ovarian cancer prognosis.卵巢癌预后生物标志物的现状
Future Oncol. 2015;11(23):3187-95. doi: 10.2217/fon.15.251. Epub 2015 Nov 9.
9
BCL7A protein expression in normal and malignant lymphoid tissues.BCL7A蛋白在正常及恶性淋巴组织中的表达
Br J Haematol. 2013 Jan;160(1):106-9. doi: 10.1111/bjh.12080. Epub 2012 Oct 9.
10
Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage cutaneous T-cell lymphoma.在早期皮肤T细胞淋巴瘤患者中,BCL7A表达缺失与疾病预后不良相关。
Leuk Lymphoma. 2013 Mar;54(3):653-4. doi: 10.3109/10428194.2012.717695. Epub 2012 Aug 28.